SlideShare a Scribd company logo

Biosimilar Development EPTM 2015

Sharing my learning in dealing with complexity and uncertainty and shed some light on: (a) Understanding the ‘biosimilar paradox’ (b) Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’ (c) In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs (D) Invite the audience to get to know NIPTE and provide us ways to collaborate with industry

1 of 25
Download to read offline
Biosimilar Development
Our “QbD” Journey from Generics to Biosimilars
Ajaz S. Hussain, Ph.D.
The National Institute of Pharmaceutical Technology & Education, Inc.
& Insight Advice and Solutions LLC.
Celebrating 54 Years
September 25, 2015, Basking Ridge, NJ
9/24/2015 ajaz@nipte.org 1
Biosimilars @ US FDA: Current state
57 products in review, 16 reference products
• New Review paradigm; totality of evidence – putting analytics first
• Advisory committee process (Zarxio®; ‘totality of evidence’ making the case to clinicians poses challenges)
• Final Guidance documents
• Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012)
• Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (2012)
• Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
(2012)
• Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants (2013)
• Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (2014)
• Other documents
• Purple book
• Draft guidance Naming, labeling
• Planned guidance Statistical approaches to analytical similarity
• Planned guidance Interchangeability
• Building confidence – education?
• 30 years of Generics; still we have confidence challenges
• How will we build confidence in ‘biosimilars’?
9/24/2015 ajaz@nipte.org 2
9/24/2015 ajaz@nipte.org 3
generics are for minor but
not serious illnesses;… and
poor people are forced to
‘settle’ for generics.
What do people really think of generic medicines? A systematic review and
critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Medicine 2015, 13:173
36 % of the patients reported negative
experiences after medication substitution
89 % of pharmacists reported receiving
patient complaints regarding use of generic
medicine, although 64 % suggested that this
was due to a nocebo effect
Only 50.2 % of the surveyed pharmacists
agreed that all products that were
approved as generic equivalents can be
considered therapeutically equivalent.
Just 6 % of pharmacists considered
that dry powder inhalers were
interchangeable.
While acceptance of generic medications is improving, substantial mistrust and lack of confidence remains,
particularly within the patient and, to a lesser extent, physician groups.
Nearly half the patients stated they would
refuse generic substitution when it became
available if this was just to save the health
authority money.
Generic medicines were
considered to be poor quality and
treated with suspicion.
Zarzio® (EU) & Zarxio® (US)
EP2006
Zarzio®
Zarxio®
US‐NeupogenEU‐Neupogen
9/24/2015 ajaz@nipte.org 4
Highly similar
Interchangeable?Highly similar
Highly similar
Extrapolation of indications; easier Extrapolation of indications; difficult
Finger-print like similarity; statistical confidence
Products and Trade-marks of Sandoz
This talk: My objectives
• To share my learning in dealing with complexity and uncertainty and
shed some light on
• Understanding the ‘biosimilar paradox’
• Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’
• In preparing this talk, collect my thoughts to help NIPTE consider ways for
developing its program on Biosimilars to help the Nation improve assurance
of quality with confidence and lower costs
• Invite the audience to get to know NIPTE and provide us ways to collaborate
with industry
9/24/2015 ajaz@nipte.org 5
9/24/2015 ajaz@nipte.org 6
A unique, non-profit consortium of pharmaceutical
science and engineering programs across 14 major
research universities. Lowering cost & enhancing
confidence……
Biosimilars Group
Analytical Comparison of Parent and
Follow-On Biologics to Aid Biosimilars
Regulatory Guidelines Development
•Lead: Anna Schwendeman
•Institution: University of Michigan
Physiochemical and Biological
Evaluations of Different IgG1Fc
Glycoforms as a Model of Biosimilar
Comparability Analysis
•Lead: Thomas Tolbert
•Institution: University of Kansas
http://www.nipte.org/

Recommended

applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsRichard Littlewood
 
BioProcess International Keynote
BioProcess International KeynoteBioProcess International Keynote
BioProcess International Keynotevandenboom
 
Reducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentReducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentAjaz Hussain
 
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...Canadian Cancer Survivor Network
 
CBI Biosimilars Workshop
CBI Biosimilars WorkshopCBI Biosimilars Workshop
CBI Biosimilars Workshopvandenboom
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Debashish Kar
 
Biosimilars-emerging market in india
Biosimilars-emerging market in indiaBiosimilars-emerging market in india
Biosimilars-emerging market in indiaPRUTHVIRAJ. U
 
U.S. Regulation of Biosimilars
U.S. Regulation of BiosimilarsU.S. Regulation of Biosimilars
U.S. Regulation of BiosimilarsMichael Swit
 

More Related Content

What's hot

Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Joseph Pategou
 
A Report on Pipeline of Biosimilars in India 2015
A Report on Pipeline of Biosimilars in India 2015 A Report on Pipeline of Biosimilars in India 2015
A Report on Pipeline of Biosimilars in India 2015 fydmanagementconsultants
 
Update on U.S. Regulation of Biosimilars
Update on U.S. Regulation of BiosimilarsUpdate on U.S. Regulation of Biosimilars
Update on U.S. Regulation of BiosimilarsMichael Swit
 
BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends    BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison Joseph Pategou
 
Global regulatory landscape of biosimilars
Global regulatory landscape of biosimilarsGlobal regulatory landscape of biosimilars
Global regulatory landscape of biosimilars碩彥 徐
 
Biosimilars: Overview of the New U.S. Pathway
Biosimilars:  Overview of the New U.S. PathwayBiosimilars:  Overview of the New U.S. Pathway
Biosimilars: Overview of the New U.S. PathwayMichael Swit
 
Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Allied Market Research
 
Biosimilars and Development
Biosimilars and DevelopmentBiosimilars and Development
Biosimilars and DevelopmentLikith `HV
 
Clinical development of biopharmaceuticals in India
Clinical development of biopharmaceuticals in IndiaClinical development of biopharmaceuticals in India
Clinical development of biopharmaceuticals in IndiaBhaswat Chakraborty
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Rollrahulranjan138
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketJoanne Toran McHugh
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)TGA Australia
 

What's hot (20)

Biosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 SlidesBiosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 Slides
 
Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues
 
A Report on Pipeline of Biosimilars in India 2015
A Report on Pipeline of Biosimilars in India 2015 A Report on Pipeline of Biosimilars in India 2015
A Report on Pipeline of Biosimilars in India 2015
 
Biosimilars
Biosimilars Biosimilars
Biosimilars
 
Update on U.S. Regulation of Biosimilars
Update on U.S. Regulation of BiosimilarsUpdate on U.S. Regulation of Biosimilars
Update on U.S. Regulation of Biosimilars
 
BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends    BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends
 
Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison      Biosimilars and Generics: A Comparison
Biosimilars and Generics: A Comparison
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
Biosimilar - a mAb case study
Biosimilar - a mAb case studyBiosimilar - a mAb case study
Biosimilar - a mAb case study
 
Donald R. Ware, Assessing the Viability of FDA's Biosimilars Pathway
Donald R. Ware, Assessing the Viability of FDA's Biosimilars PathwayDonald R. Ware, Assessing the Viability of FDA's Biosimilars Pathway
Donald R. Ware, Assessing the Viability of FDA's Biosimilars Pathway
 
Life of a Biosimilar
Life of a BiosimilarLife of a Biosimilar
Life of a Biosimilar
 
What are Supergenerics
What are SupergenericsWhat are Supergenerics
What are Supergenerics
 
Global regulatory landscape of biosimilars
Global regulatory landscape of biosimilarsGlobal regulatory landscape of biosimilars
Global regulatory landscape of biosimilars
 
Biosimilars: Overview of the New U.S. Pathway
Biosimilars:  Overview of the New U.S. PathwayBiosimilars:  Overview of the New U.S. Pathway
Biosimilars: Overview of the New U.S. Pathway
 
Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market
 
Biosimilars and Development
Biosimilars and DevelopmentBiosimilars and Development
Biosimilars and Development
 
Clinical development of biopharmaceuticals in India
Clinical development of biopharmaceuticals in IndiaClinical development of biopharmaceuticals in India
Clinical development of biopharmaceuticals in India
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Roll
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar Market
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
 

Viewers also liked

Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...
Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...
Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...Ajaz Hussain
 
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017Ajaz Hussain
 
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 Final
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 FinalNIPTE Conference 2016 Keynote Ajaz Hussain 09272016 Final
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 FinalAjaz Hussain
 
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015Ajaz Hussain
 
Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015Ajaz Hussain
 
Visioning the Next Decade: NIPTE-FDA Collaboration
Visioning the Next Decade: NIPTE-FDA CollaborationVisioning the Next Decade: NIPTE-FDA Collaboration
Visioning the Next Decade: NIPTE-FDA CollaborationAjaz Hussain
 
Biosimilars Advantages and Disadvantages
Biosimilars Advantages and DisadvantagesBiosimilars Advantages and Disadvantages
Biosimilars Advantages and DisadvantagesVeeda CR
 
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016 Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016 Ajaz Hussain
 
Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016Ajaz Hussain
 
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Ajaz Hussain
 
Biopharmaceutics Classification System (BCS) & Waiver of Bioequivalence
Biopharmaceutics Classification System (BCS) & Waiver of BioequivalenceBiopharmaceutics Classification System (BCS) & Waiver of Bioequivalence
Biopharmaceutics Classification System (BCS) & Waiver of BioequivalenceAjaz Hussain
 
FDA Trend: New Validation Strategies
FDA Trend: New Validation StrategiesFDA Trend: New Validation Strategies
FDA Trend: New Validation StrategiesAjaz Hussain
 
Regulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical ManufacturingRegulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical ManufacturingAjaz Hussain
 
An Overview of Biologics Manufacturing Processes and Things to Consider from ...
An Overview of Biologics Manufacturing Processes and Things to Consider from ...An Overview of Biologics Manufacturing Processes and Things to Consider from ...
An Overview of Biologics Manufacturing Processes and Things to Consider from ...WPICPE
 
As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...Steven S. Lee
 
Celltrion Healthcare 102 weeks with Remsima(HCP)
Celltrion Healthcare 102 weeks with Remsima(HCP)Celltrion Healthcare 102 weeks with Remsima(HCP)
Celltrion Healthcare 102 weeks with Remsima(HCP)celltrionh
 
Health economics models and interchangeability of drugs v1.0
Health economics models and interchangeability of drugs v1.0Health economics models and interchangeability of drugs v1.0
Health economics models and interchangeability of drugs v1.0Goran Medic
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)celltrionh
 

Viewers also liked (20)

Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...
Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...
Complex Generics Developing Defensible Statistical Analyses and Acceptance Cr...
 
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
 
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 Final
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 FinalNIPTE Conference 2016 Keynote Ajaz Hussain 09272016 Final
NIPTE Conference 2016 Keynote Ajaz Hussain 09272016 Final
 
How dissimilarly similar are biosimilars
How dissimilarly similar are biosimilarsHow dissimilarly similar are biosimilars
How dissimilarly similar are biosimilars
 
Hussain1
Hussain1Hussain1
Hussain1
 
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
 
Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015
 
Visioning the Next Decade: NIPTE-FDA Collaboration
Visioning the Next Decade: NIPTE-FDA CollaborationVisioning the Next Decade: NIPTE-FDA Collaboration
Visioning the Next Decade: NIPTE-FDA Collaboration
 
Biosimilars Advantages and Disadvantages
Biosimilars Advantages and DisadvantagesBiosimilars Advantages and Disadvantages
Biosimilars Advantages and Disadvantages
 
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016 Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
 
Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016
 
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016
 
Biopharmaceutics Classification System (BCS) & Waiver of Bioequivalence
Biopharmaceutics Classification System (BCS) & Waiver of BioequivalenceBiopharmaceutics Classification System (BCS) & Waiver of Bioequivalence
Biopharmaceutics Classification System (BCS) & Waiver of Bioequivalence
 
FDA Trend: New Validation Strategies
FDA Trend: New Validation StrategiesFDA Trend: New Validation Strategies
FDA Trend: New Validation Strategies
 
Regulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical ManufacturingRegulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical Manufacturing
 
An Overview of Biologics Manufacturing Processes and Things to Consider from ...
An Overview of Biologics Manufacturing Processes and Things to Consider from ...An Overview of Biologics Manufacturing Processes and Things to Consider from ...
An Overview of Biologics Manufacturing Processes and Things to Consider from ...
 
As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...
 
Celltrion Healthcare 102 weeks with Remsima(HCP)
Celltrion Healthcare 102 weeks with Remsima(HCP)Celltrion Healthcare 102 weeks with Remsima(HCP)
Celltrion Healthcare 102 weeks with Remsima(HCP)
 
Health economics models and interchangeability of drugs v1.0
Health economics models and interchangeability of drugs v1.0Health economics models and interchangeability of drugs v1.0
Health economics models and interchangeability of drugs v1.0
 
Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)Celltrion Healthcare Company Brochure(2016)
Celltrion Healthcare Company Brochure(2016)
 

Similar to Biosimilar Development EPTM 2015

BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechMaRS Discovery District
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREADPinky Fadullon
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)chetanpatel73
 
Nutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryNutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryTom McNulty
 
Evolving Regulation of Biosimilars and Update on Generic Drug Regulation
Evolving Regulation of Biosimilars and Update on Generic Drug RegulationEvolving Regulation of Biosimilars and Update on Generic Drug Regulation
Evolving Regulation of Biosimilars and Update on Generic Drug RegulationMichael Swit
 
2013 màster upf josep m. badenas
2013 màster upf josep m. badenas2013 màster upf josep m. badenas
2013 màster upf josep m. badenasJosep-Maria Badenas
 
4440642.ppt
4440642.ppt4440642.ppt
4440642.pptARUNNT2
 
Biosimilars Presentation - Health Canada
Biosimilars Presentation - Health CanadaBiosimilars Presentation - Health Canada
Biosimilars Presentation - Health CanadaNatalie Richardson
 
Developing Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsDeveloping Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsMichele Johnson
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsSandoz
 
SMi Group's Biosimilars & Biobetters conference
SMi Group's Biosimilars & Biobetters conference SMi Group's Biosimilars & Biobetters conference
SMi Group's Biosimilars & Biobetters conference Dale Butler
 
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...Michael Swit
 
Key Issues Impacting the Future of Biosimilars
Key Issues Impacting the Future of BiosimilarsKey Issues Impacting the Future of Biosimilars
Key Issues Impacting the Future of BiosimilarsMichael Swit
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
 
Download Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisDownload Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsCovance
 
What Do Doctors Think About Biosimilars?
What Do Doctors Think About Biosimilars?What Do Doctors Think About Biosimilars?
What Do Doctors Think About Biosimilars?Small World Social
 

Similar to Biosimilar Development EPTM 2015 (20)

BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of Biotech
 
Biosimilar Dug Development
Biosimilar Dug DevelopmentBiosimilar Dug Development
Biosimilar Dug Development
 
federal reserve.
federal reserve.federal reserve.
federal reserve.
 
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
(2286) World Orphan Drug Congress USA 2016 A4 32 Page Brochure 1.5 SCREEN SPREAD
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)
 
Nutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummaryNutraceutical-ExecutiveSummary
Nutraceutical-ExecutiveSummary
 
Evolving Regulation of Biosimilars and Update on Generic Drug Regulation
Evolving Regulation of Biosimilars and Update on Generic Drug RegulationEvolving Regulation of Biosimilars and Update on Generic Drug Regulation
Evolving Regulation of Biosimilars and Update on Generic Drug Regulation
 
2013 màster upf josep m. badenas
2013 màster upf josep m. badenas2013 màster upf josep m. badenas
2013 màster upf josep m. badenas
 
4440642.ppt
4440642.ppt4440642.ppt
4440642.ppt
 
Biosimilars Presentation - Health Canada
Biosimilars Presentation - Health CanadaBiosimilars Presentation - Health Canada
Biosimilars Presentation - Health Canada
 
Developing Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsDeveloping Cell Specific Cancer Treatments
Developing Cell Specific Cancer Treatments
 
Michael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation finalMichael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation final
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilars
 
SMi Group's Biosimilars & Biobetters conference
SMi Group's Biosimilars & Biobetters conference SMi Group's Biosimilars & Biobetters conference
SMi Group's Biosimilars & Biobetters conference
 
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...
The Future of BioSimilars, BioGenerics, Follow-On Biologics – A Rose by Any O...
 
Key Issues Impacting the Future of Biosimilars
Key Issues Impacting the Future of BiosimilarsKey Issues Impacting the Future of Biosimilars
Key Issues Impacting the Future of Biosimilars
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysis
 
Download Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisDownload Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysis
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for Biosimilars
 
What Do Doctors Think About Biosimilars?
What Do Doctors Think About Biosimilars?What Do Doctors Think About Biosimilars?
What Do Doctors Think About Biosimilars?
 

More from Ajaz Hussain

A Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbsA Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbsAjaz Hussain
 
SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024Ajaz Hussain
 
Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience Ajaz Hussain
 
Critical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdfCritical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdfAjaz Hussain
 
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdfValidation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdfAjaz Hussain
 
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdfSMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdfAjaz Hussain
 
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...Ajaz Hussain
 
An Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdfAn Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdfAjaz Hussain
 
Mature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and QuantitiesMature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and QuantitiesAjaz Hussain
 
I-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdfI-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdfAjaz Hussain
 
Sustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's RealitiesSustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's RealitiesAjaz Hussain
 
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...Ajaz Hussain
 
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...Ajaz Hussain
 
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...Ajaz Hussain
 
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbDPharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbDAjaz Hussain
 
Meaning making measurement maturity and management moksha
Meaning making measurement maturity and management mokshaMeaning making measurement maturity and management moksha
Meaning making measurement maturity and management mokshaAjaz Hussain
 
Equivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management SystemsEquivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management SystemsAjaz Hussain
 
Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients Ajaz Hussain
 
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...Ajaz Hussain
 
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Ajaz Hussain
 

More from Ajaz Hussain (20)

A Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbsA Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbs
 
SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024
 
Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience
 
Critical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdfCritical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdf
 
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdfValidation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdf
 
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdfSMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
 
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
 
An Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdfAn Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdf
 
Mature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and QuantitiesMature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and Quantities
 
I-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdfI-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdf
 
Sustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's RealitiesSustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's Realities
 
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
 
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...
 
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
 
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbDPharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
 
Meaning making measurement maturity and management moksha
Meaning making measurement maturity and management mokshaMeaning making measurement maturity and management moksha
Meaning making measurement maturity and management moksha
 
Equivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management SystemsEquivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management Systems
 
Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients
 
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
 
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
 

Recently uploaded

INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGINFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGJuliethKabirigi1
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERKanhu Charan
 
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptx
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptxEUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptx
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptxDr. Sumit KUMAR
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaNHS Hospital
 
Anatomy and Histology of Skin(Dermis & Epidermis).pptx
Anatomy and Histology  of Skin(Dermis & Epidermis).pptxAnatomy and Histology  of Skin(Dermis & Epidermis).pptx
Anatomy and Histology of Skin(Dermis & Epidermis).pptxMathew Joseph
 
gynae pcd pharma franchise - Solace Biotech Limited
gynae pcd pharma franchise -  Solace Biotech Limitedgynae pcd pharma franchise -  Solace Biotech Limited
gynae pcd pharma franchise - Solace Biotech LimitedSBL DIGITAL
 
Death or Thantology.pptx death ppt useful ppt
Death or Thantology.pptx death ppt useful pptDeath or Thantology.pptx death ppt useful ppt
Death or Thantology.pptx death ppt useful pptDrSathishMS1
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effectsbkling
 
Clinical validation of an Artificial Intelligence algorithm for the detection...
Clinical validation of an Artificial Intelligence algorithm for the detection...Clinical validation of an Artificial Intelligence algorithm for the detection...
Clinical validation of an Artificial Intelligence algorithm for the detection...Josep Vidal-Alaball
 
Yantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaYantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaAparnaNandakumar12
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxSai Sailesh Kumar Goothy
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyAkshay Shetty
 
Finger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxFinger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxAlawode Samuel2
 
Radicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystRadicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystJani253068
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfMedicoseAcademics
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJuliethKabirigi1
 

Recently uploaded (20)

INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEGINFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
INFECTIVE ENDOCARDITIS-BLOOD CULTURE NEG
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCER
 
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptx
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptxEUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptx
EUTHANASIA: WORLD AND INDIAN PERSPECTIVEpptx
 
Best neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab IndiaBest neurologist in jalandhar Punjab India
Best neurologist in jalandhar Punjab India
 
Anatomy and Histology of Skin(Dermis & Epidermis).pptx
Anatomy and Histology  of Skin(Dermis & Epidermis).pptxAnatomy and Histology  of Skin(Dermis & Epidermis).pptx
Anatomy and Histology of Skin(Dermis & Epidermis).pptx
 
gynae pcd pharma franchise - Solace Biotech Limited
gynae pcd pharma franchise -  Solace Biotech Limitedgynae pcd pharma franchise -  Solace Biotech Limited
gynae pcd pharma franchise - Solace Biotech Limited
 
Death or Thantology.pptx death ppt useful ppt
Death or Thantology.pptx death ppt useful pptDeath or Thantology.pptx death ppt useful ppt
Death or Thantology.pptx death ppt useful ppt
 
Ways to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side EffectsWays to Manage Ovarian Cancer Treatment Side Effects
Ways to Manage Ovarian Cancer Treatment Side Effects
 
Clinical validation of an Artificial Intelligence algorithm for the detection...
Clinical validation of an Artificial Intelligence algorithm for the detection...Clinical validation of an Artificial Intelligence algorithm for the detection...
Clinical validation of an Artificial Intelligence algorithm for the detection...
 
Yantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in AyurvedaYantropakaranani 2: Heating Devices used in Ayurveda
Yantropakaranani 2: Heating Devices used in Ayurveda
 
A case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage femaleA case of Trichobezoar in a teenage female
A case of Trichobezoar in a teenage female
 
Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29Pancreatic Cancer an Overview - CCSN 2024-02-29
Pancreatic Cancer an Overview - CCSN 2024-02-29
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptx
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay Shetty
 
A rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid TorsionA rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid Torsion
 
A Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptxA Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptx
 
Finger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxFinger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptx
 
Radicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cystRadicular cyst or periapical odontogenic cyst
Radicular cyst or periapical odontogenic cyst
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdf
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
 

Biosimilar Development EPTM 2015

  • 1. Biosimilar Development Our “QbD” Journey from Generics to Biosimilars Ajaz S. Hussain, Ph.D. The National Institute of Pharmaceutical Technology & Education, Inc. & Insight Advice and Solutions LLC. Celebrating 54 Years September 25, 2015, Basking Ridge, NJ 9/24/2015 ajaz@nipte.org 1
  • 2. Biosimilars @ US FDA: Current state 57 products in review, 16 reference products • New Review paradigm; totality of evidence – putting analytics first • Advisory committee process (Zarxio®; ‘totality of evidence’ making the case to clinicians poses challenges) • Final Guidance documents • Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2012) • Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (2012) • Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (2012) • Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants (2013) • Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (2014) • Other documents • Purple book • Draft guidance Naming, labeling • Planned guidance Statistical approaches to analytical similarity • Planned guidance Interchangeability • Building confidence – education? • 30 years of Generics; still we have confidence challenges • How will we build confidence in ‘biosimilars’? 9/24/2015 ajaz@nipte.org 2
  • 3. 9/24/2015 ajaz@nipte.org 3 generics are for minor but not serious illnesses;… and poor people are forced to ‘settle’ for generics. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Medicine 2015, 13:173 36 % of the patients reported negative experiences after medication substitution 89 % of pharmacists reported receiving patient complaints regarding use of generic medicine, although 64 % suggested that this was due to a nocebo effect Only 50.2 % of the surveyed pharmacists agreed that all products that were approved as generic equivalents can be considered therapeutically equivalent. Just 6 % of pharmacists considered that dry powder inhalers were interchangeable. While acceptance of generic medications is improving, substantial mistrust and lack of confidence remains, particularly within the patient and, to a lesser extent, physician groups. Nearly half the patients stated they would refuse generic substitution when it became available if this was just to save the health authority money. Generic medicines were considered to be poor quality and treated with suspicion.
  • 4. Zarzio® (EU) & Zarxio® (US) EP2006 Zarzio® Zarxio® US‐NeupogenEU‐Neupogen 9/24/2015 ajaz@nipte.org 4 Highly similar Interchangeable?Highly similar Highly similar Extrapolation of indications; easier Extrapolation of indications; difficult Finger-print like similarity; statistical confidence Products and Trade-marks of Sandoz
  • 5. This talk: My objectives • To share my learning in dealing with complexity and uncertainty and shed some light on • Understanding the ‘biosimilar paradox’ • Accelerating our “QbD” Journey – focusing on ‘from Generics to Biosimilars’ • In preparing this talk, collect my thoughts to help NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs • Invite the audience to get to know NIPTE and provide us ways to collaborate with industry 9/24/2015 ajaz@nipte.org 5
  • 6. 9/24/2015 ajaz@nipte.org 6 A unique, non-profit consortium of pharmaceutical science and engineering programs across 14 major research universities. Lowering cost & enhancing confidence…… Biosimilars Group Analytical Comparison of Parent and Follow-On Biologics to Aid Biosimilars Regulatory Guidelines Development •Lead: Anna Schwendeman •Institution: University of Michigan Physiochemical and Biological Evaluations of Different IgG1Fc Glycoforms as a Model of Biosimilar Comparability Analysis •Lead: Thomas Tolbert •Institution: University of Kansas http://www.nipte.org/
  • 7. My viewpoints and interests Viewpoints • US FDA • SUPACs, BCS,….PAT, QbD, Integrations of Office of Biotechnology within CDER • Sandoz • Omnitrope®, Binocrit®, Zarzio®, generic enoxaparin, generic glatiramer acetate • Philip Morris International • Plant based vaccines and modified-risk tobacco products • Reconnecting with India • Wockhardt and current advisory practice in India – Culture of Pharmaceutical Quality Interests • NIPTE consider ways for developing its program on Biosimilars to help the Nation improve assurance of quality with confidence and lower costs • Insight Advice and Solutions LLC., Allocated time filled-up; not accepting new clients until the end of 2016 9/24/2015 ajaz@nipte.org 7
  • 8. In the news; past few days Sept. 24, 2015 Novartis in biosimilar push to cut US drug prices: The introduction of biosimilar drugs in the US, which kicked off this month with Novartis’s version of an Amgen blockbuster, hands healthcare payers a new weapon against rising drug prices. Sept. 23, 2015 Amgen, Allergan Biosimilar Lung-Cancer Therapy Shows Positive Results: ABP 215 is being developed as a biosimilar to Roche’s Avastin Sept. 22, 2015 Lack of regulatory clarity dominates US biosimilar debates post Zarxio®: Sandoz has reiterated its call for US FDA guidance on biosimilar interchangeability arguing that the lack of clarity makes it hard to gauge what impact switching rules will have on pricing. 9/24/2015 ajaz@nipte.org 8
  • 9. First Biosimilar Medicine Launches; Price Disappoints Those Hoping For Deeper Discount Forbes | Opinion Sept. 15, 2015 Chart using 2014 data. Retrieved from Rand Corporation, September 14, 2015. “..could reduce spending on biologics in the United States by $44 billion over the next decade..” Chart using 2013 data. Retrieved from Express Scripts, September 14, 2015. Another biosimilar is coming along that could actually cost taxpayers a higher price!!! 9/24/2015 ajaz@nipte.org 9
  • 10. ‘Biosimilar Paradox’ 9/24/2015 ajaz@nipte.org 10 http://invivoblog.blogspot.com/2007/08/are-these-large-molecule-twins.html •Not Similar; Similar; Highly Similar; Highly similar; fingerprint-like similarity ; Interchangeable •Barriers to Market Entry - Commercial Success Disappointing •(Will) there will be significant savings for the U.S. Medicare and Medicaid programs? •US is not Europe! Zarzio® (EU) & Zarxio® (US)•
  • 11. Biosimilar Paradox: EU Aug., 10 2007 • But despite Europe's pioneering regulatory pathway for biosimilars, and reluctant grunts of acceptance from originator companies, most of which have realized that it’s pointless and counterproductive to keep resisting the biosimilar movement, the going’s tough, according to Ajaz Hussain, Sandoz’s VP and Global Head of Biopharmaceutical Development. • One might expect a drug that sells at a 20-30% discount—he did confirm this much--to fly off the shelves, given all the fuss around Amgen’s monopoly over EPO supply…..and the noise that most European governments and US payors are making about drug costs. But education and perception are blocking widespread uptake…. 9/24/2015 ajaz@nipte.org 11
  • 12. Biosimilar Paradox: Promises & Perils Steep discounts help biotech drug copies gain ground in Europe: Biosimilar antibody drug prices fall faster than expected ( Sept. 23, 2015, Reuters). But US is not Europe! Zarzio® (EU) & Zarxio® (US) There will be significant savings for the U.S. Medicare and Medicaid programs? CBO estimates savings of ~$25 billion between 2013 and 2020. How to build confidence, cost savings, and commercial success? Assessing Valuation Risk of Big Pharma Companies: Forbes | Investing (Sept. 21, 2015) J&J’s Remicade Revenues May See Significant Decline Merck May Actually Be Well Off In The Near Term Pfizer Seems To Have Upside Possibility Bristol-Myers Squibb’s Risk Lies A Few Years Ahead Roche Might Be Vulnerable, But Will Fiercely Defend Barriers to Market Entry: It takes 7 to 8 years to develop a biosimilar, at a cost of between $100 million and $250 million: Commercial Success (Currently) Disappointing ? ? 9/24/2015 ajaz@nipte.org 12
  • 13. FDA's Woodcock to Senators: Need to First Get the Science Right on Biosimilars • Sept., 17 2015 • "We have to get the science right. We can't have problems with the first biosimilars out of the block" • One of the most important parts of launching a robust US biosimilar market and setting up the regulations to support it is to make sure the scientific framework is "bulletproof” • Key issues remaining - FDA guidance on interchangeability and the difficulties behind developing, naming and labeling • "We've laid out a plan of education campaigns and still need to determine what people need to know“ • It's a complicated issue so we have a menu of educational activities for the next several years“ • Does this mean the EU didn’t get its “science right”? No! 9/24/2015 ajaz@nipte.org 13
  • 14. Essentially taken for granted  paying attention is the critical factor......... To understand this Paradox: Understand our “QbD” Journey from Generics to Biosimilars The Hatch-Waxman Act of 1984: Successfully contained the cost of small-molecule drugs; based on the [PE + BE = TE] paradigm [PE + BE = TE] paradigm struggles to deal with complexity; including Complex Generics The Biologics Price Competition & Innovation Act 2009: pathway for Biosimilars; recognizing the complexity; a high bar! PE = Pharmaceutical equivalence: BE = Bioequivalence TE = Therapeutic equivalence 9/24/2015 ajaz@nipte.org 14
  • 15. Our “generic” paradigm: Interchangeability with confidence 9/24/2015 ajaz@nipte.org 15 Pharmaceutical Equivalence Bio-equivalence Practices > Confidence Therapeutic Equivalence
  • 16. Generic paradigm has been tested and “knocked on its head” • “It still is solid” but in need for attention – particularly in the realm of complex generics • “Knocks on the head” • Generic Drug Scandal • Failures to detect obvious errors/flaws • Recent failures and manufacturing challenges • Tested – numerous prospective studies to assess therapeutic equivalence 9/24/2015 ajaz@nipte.org 16
  • 17. “Knocks on the head” erode confidence and increase nocebo effects! • “Knocks on the head” have occurred • When we failed to appreciate a systems approach to development, review, process validation, and inspections (GLP/GCP/CGMPs) • When we ignored to ask the ‘right question’ and in the ‘right sequence’ • When we did not question assumptions we take for granted • Most of these relate to Pharmaceutical Equivalence • PE = dosage form (irrespective of color, shape, mechanism of release,….); • A clear liquid in a bottle is a “solution”: e.g., cyclosporine micro emulsion, and low- permeability excipients (e.g., sorbitol) • Consider current examples….ER failures and AB to BX downgrades • Our incorrect thinking – “BE is the pivotal evidence”; instead of integrating PE,BE, Practices – as in a system 9/24/2015 ajaz@nipte.org 17
  • 18. “Pharmaceutical Equivalence” that is the ‘Elephant in the Dark’ • Q1/Q2 • Q1/Q2/Q3, …… • Today … Color, Shape,…..moving towards same mechanism of release? • Today we are back to “subjectXformulation” interaction – once again in healthy subjects? • Isn't this just an assumption? Which, politely, is not a part of “our elephant” but what comes out of it when we don’t pay attention to PE! • We lack consensus on a set of principles to integrate across multiple, orthogonal, analytical characterization tools for physical attributes and physical performance (e.g., size, shape, charge, flow, plume, …) • This is a “billion dollar” opportunity; but only for certain companies 9/24/2015 ajaz@nipte.org 18
  • 19. 9/24/2015 ajaz@nipte.org 19 Ajaz Hussain. Reducing technical and regulatory uncertainty in biosimilar development (2014) Value of extensive analytical characterization Leveraging variability to reduce uncertainty in interchangeability
  • 20. The “how” is very difficult because of “culture” and “mind-set” 9/24/2015 ajaz@nipte.org 20 Characterization of Brand Copaxone Thorough understanding of reference listed drug (Copaxone) required. Review available scientific, patent, and regulatory literature on Copaxone. Characterizationby more than 60 physicochemical, biological, and immunological methods. Multiple lots (up to 50 for some attributes) were studied over several years probing the range and diversity of the commercial lots, as well as evaluating the effects of lot aging. Four-Point Criteria for Demonstration of Equivalence of Glatopa and Copaxone Equivalenceof starting materials and basic chemistry. Equivalenceof structural signatures for polymerization, depolymerization, and purification. Equivalenceof physicochemicalproperties. Equivalenceof biologicaland immunological properties. Example: Equivalence considerations for Glatopa® and Copaxone® http://www.momentapharma.com/AAN-Equivalence-Glatopa-Poster-6x4-PRESS.pdf (accessed 16 September 2015)
  • 21. 9/24/2015 ajaz@nipte.org 21 Ajaz Hussain. Reducing technical and regulatory uncertainty in biosimilar development (2014)
  • 22. 9/24/2015 ajaz@nipte.org 22 Residual uncertainty; perhaps reserved for uncertainty in extrapolation to some indications Ajaz Hussain. Reducing technical and regulatory uncertainty in biosimilar development (2014)
  • 23. Biosimilar: Totality of Evidence • New Review Paradigm – meeting format • Focus first on analytical characterization and comparability • Totality of evidence evolves – based on residual uncertainty • Is this a better – formalized- approach than for complex generics? • For Complex Generics OGD has been willing to meet with sponsors more often • However, time for complex generic approval is very protracted 9/24/2015 ajaz@nipte.org 23
  • 24. Complex Generics & Biosimilars: What we need? • Put R back in R&D & recognize It is a “complex” product and process! • Invest smartly in analytics, mathematics & statistics, and large sample sizes; and in systems/integrative thinking and data integration • Get to know the RLD – multiple lots; open the door with large sample size • Build capability to justify measured RLD variability is relevant to development of the proposed generic/biosimilar • Exquisite regulatory communication strategy • This is not a ‘complicated process’ for which typical “good practices” will work seamlessly (e.g., typical project management approach); this is a complex process – with multiple interactions and “emergent properties” • Treat it as it is - a complex process and plan; anticipate and address “emergent issues” - in technical, regulatory and legal dimensions; at a certain point be prepared for stakeholder (payers, patient groups,..) communications 9/24/2015 ajaz@nipte.org 24
  • 25. NIPTE: The Nation Needs • Seamless scientific logic bridging different legal and regulatory pathways • Accelerate achieving consensus on a set of generalizable principles for integrating information across multiple, orthogonal, analytical characterization tools for chemical, biological and physical attributes; to predict product performance, and estimate and describe residual uncertainty • Consider categories such as peptides (synthetic and recombinant) as a bridge between Generics and Biosimilars to achieve a ‘seamless scientific logic’ • The Nation needs the scientific & regulatory community to achieve this quickly – so that efforts to educate to build confidence, in the health care community and with patients, can begin 9/24/2015 ajaz@nipte.org 25